These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17113217)

  • 1. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer.
    Maffezzini M; Bossi A; Collette L
    Eur Urol; 2007 Mar; 51(3):605-13; discussion 613. PubMed ID: 17113217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer.
    Vicini FA; Vargas C; Abner A; Kestin L; Horwitz E; Martinez A
    J Urol; 2005 May; 173(5):1456-62. PubMed ID: 15821460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH
    Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
    Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
    BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PSA doubling time and method of calculation].
    Ruffion A; Rebillard X; Grima F
    Prog Urol; 2005 Dec; 15(6):1035-41. PubMed ID: 16429649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSA recurrence: definitions, PSA kinetics, and identifying patients at risk.
    Klotz LH
    Can J Urol; 2006 Apr; 13 Suppl 2():43-7. PubMed ID: 16672128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
    Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
    J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
    Stock RG; Klein TJ; Cesaretti JA; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
    Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
    Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
    Ganzer R; Rogenhofer S; Walter B; Lunz JC; Schostak M; Wieland WF; Blana A
    Eur Urol; 2008 Mar; 53(3):547-53. PubMed ID: 17662520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
    Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
    Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining if pretreatment PSA doubling time predicts PSA trajectories after radiation therapy for localized prostate cancer.
    Soto DE; Andridge RR; Pan CC; Williams SG; Taylor JM; Sandler HM
    Radiother Oncol; 2009 Mar; 90(3):389-94. PubMed ID: 18977051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
    Klotz L
    Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical relapse of prostate cancer. Evidence after radical surgery.
    Prott FJ; Spitz J; Michaelis M; Niles B; Barth S; Köllermann M; Kleinschmidt K
    Anticancer Res; 2003; 23(2A):979-81. PubMed ID: 12820334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.